<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00527046</url>
  </required_header>
  <id_info>
    <org_study_id>A257-102</org_study_id>
    <nct_id>NCT00527046</nct_id>
  </id_info>
  <brief_title>Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Five Parallel Group Study Of The Effect Of CP-424,391 On Physical Performance And Body Composition In Older Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <brief_summary>
    <textblock>
      A 24-month, placebo controlled, double dummy, parallel-design outpatient trial in generally
      healthy elderly men and women who are at risk of becoming frail.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">October 2001</completion_date>
  <primary_completion_date type="Actual">October 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent increase in lean (non fat) body mass.</measure>
    <time_frame>Measured by DXA at BL 3, 6, 12, and 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in functional performance (speed to climb stairs, walking speed and feet walked in 6 min).</measure>
    <time_frame>Measured at BL, 3, 6, 12, and 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics, blood hormones and biomarkers</measure>
    <time_frame>(BL,3,6,12,24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tape measurement of size of arm and leg muscles, waist, and hip</measure>
    <time_frame>(BL,3,6,12,24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1 and GH levels</measure>
    <time_frame>(1,2,18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overnight GH profile in a subset</measure>
    <time_frame>(2,18 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength</measure>
    <time_frame>(BL,3,6,12,24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questionnaires on general health, depression, mental status, sleep and activities of daily living</measure>
    <time_frame>(BL,3,6,12,24 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other physical performance tests including time to rise from a chair 5 times, balance tests (walking a straight line)</measure>
    <time_frame>(BL,3,6,12,24 months)</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">396</enrollment>
  <condition>Aging</condition>
  <condition>Frail Older Adults</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-424,391</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        65-84 years old, BMI &lt; 30, at risk for functional decline based on SF-36, Instrumental
        Activities of Daily Living (per Nagy's), or 2 or more falls in prior 2 years

        Exclusion Criteria:

        Significant history or symptoms of acute medical conditions, currently in an exercise
        program, pain or other conditions that would prevent participating in exercise testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Winston-salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=102&amp;StudyName=Effects+Of+An+Oral+Growth+Hormone+Secretagogue+In+Older+Functionally+Limited+Adults</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2007</study_first_submitted>
  <study_first_submitted_qc>September 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2007</study_first_posted>
  <disposition_first_submitted>January 30, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>January 30, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 2, 2012</disposition_first_posted>
  <last_update_submitted>January 30, 2012</last_update_submitted>
  <last_update_submitted_qc>January 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

